---
title: "Dongcheng Biochem: Plans to spin off its subsidiary Lanacheng for listing on the main board of the Hong Kong Stock Exchange"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255031335.md"
description: "Dongcheng Biochem announced that the company's supervisory board has approved the proposal for the spin-off of its subsidiary Yantai Lanna Cheng Biotechnology Co., Ltd. to be listed on the Main Board of the Hong Kong Stock Exchange. The initial issuance scale for Lanna is not to exceed 25% of the total expanded share capital immediately after the issuance, and grants the overall coordinator an over-allotment option of up to 15% of the aforementioned H share initial issuance scale. This spin-off listing plan needs to be submitted for approval at the company's shareholders' meeting"
datetime: "2025-08-28T13:44:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255031335.md)
  - [en](https://longbridge.com/en/news/255031335.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255031335.md)
generator: "portal-rs"
---

# Dongcheng Biochem: Plans to spin off its subsidiary Lanacheng for listing on the main board of the Hong Kong Stock Exchange

Dongcheng Biochem announced that the company's supervisory board has approved the proposal for the spin-off of its subsidiary Yantai Lanna Cheng Biotechnology Co., Ltd. to be listed on the Main Board of the Hong Kong Stock Exchange. The initial issuance scale for Lanna is not to exceed 25% of the total share capital after the issuance is expanded, and an overall coordinator is granted an over-allotment option of up to 15% of the aforementioned H-share initial issuance scale. This spin-off listing plan needs to be submitted to the company's shareholders' meeting for review

### Related Stocks

- [002675.CN](https://longbridge.com/en/quote/002675.CN.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [OncoZenge registers 772,797 shares in directed issue after SEK 5 million payment from Sichuan Yangtian](https://longbridge.com/en/news/296607308.md)
- [Lighthouse Canton favors EM high-yield sovereigns as developed-market fiscal risks rise](https://longbridge.com/en/news/296183818.md)
- [Hong Kong billionaire Keswick clan’s Jardine C&C to sell Singapore, Malaysia car dealerships to Indonesian tycoon’s firm](https://longbridge.com/en/news/296664768.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**